Article ; Online: Dendritic cell vaccination in combination with erlotinib in a patient with inoperable lung adenocarcinoma: a case report.
Journal of medical case reports
2024 Volume 18, Issue 1, Page(s) 88
Abstract: Background: Satisfactory treatment for patients with unresectable advanced lung cancer has not yet been established. We report a case of unresectable advanced lung cancer (stage IIIb: T2aN3M0) treated with a total of 15 doses of dendritic cells pulsed ... ...
| Abstract | Background: Satisfactory treatment for patients with unresectable advanced lung cancer has not yet been established. We report a case of unresectable advanced lung cancer (stage IIIb: T2aN3M0) treated with a total of 15 doses of dendritic cells pulsed with a Wilms' tumor 1 and mucin 1 vaccine in combination with erlotinib, a small molecule epidermal growth factor receptor tyrosine kinase inhibitor, for more than 699 days without recurrence or metastasis. Case presentation: A 63-year-old Korean woman was diagnosed with lung adenocarcinoma by pathology and computed tomography. The adenocarcinoma showed an epidermal growth factor receptor (EGFR) mutation, no anaplastic lymphoma kinase expression, and less than 1% expression of programmed death ligand 1. She received erlotinib alone for approximately 1 month. She then received erlotinib and the dendritic cells pulsed with Wilms' tumor 1 and mucin 1 vaccine. The diameter of the erythema at the vaccinated sites was 30 mm at 48 hours after the first vaccination. Moreover, it was maintained at more than 20 mm during the periods of vaccination. These results suggested the induction of antitumor immunity by the vaccine. Remarkably, the tumor size decreased significantly to 12 mm, a 65.7% reduction, after combined therapy with eight doses of the dendritic cells pulsed with Wilms' tumor 1 and mucin 1 vaccine and erlotinib for 237 days based on fluorodeoxyglucose uptake by positron emission tomography/computed tomography and computed tomography. Interestingly, after 321 days of combination therapy, the clinical findings improved, and no tumor was detected based on computed tomography. Validation of the tumor's disappearance persisted for at least 587 days after treatment initiation, without any indication of recurrence or metastasis. Conclusion: Standard anticancer therapy combined with the dendritic cells pulsed with Wilms' tumor 1 and mucin 1 vaccine may have therapeutic effects for such patients with unresectable lung adenocarcinoma. |
|---|---|
| MeSH term(s) | Female ; Humans ; Middle Aged ; Erlotinib Hydrochloride/therapeutic use ; Mucin-1/genetics ; Mucin-1/therapeutic use ; WT1 Proteins/genetics ; WT1 Proteins/therapeutic use ; Adenocarcinoma of Lung/drug therapy ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Wilms Tumor ; ErbB Receptors/genetics ; ErbB Receptors/therapeutic use ; Kidney Neoplasms/drug therapy ; Vaccines/therapeutic use ; Vaccination ; Dendritic Cells ; Mutation ; Protein Kinase Inhibitors/therapeutic use |
| Chemical Substances | Erlotinib Hydrochloride (DA87705X9K) ; Mucin-1 ; WT1 Proteins ; ErbB Receptors (EC 2.7.10.1) ; Vaccines ; Protein Kinase Inhibitors |
| Language | English |
| Publishing date | 2024-02-10 |
| Publishing country | England |
| Document type | Case Reports ; Journal Article |
| ZDB-ID | 2269805-X |
| ISSN | 1752-1947 ; 1752-1947 |
| ISSN (online) | 1752-1947 |
| ISSN | 1752-1947 |
| DOI | 10.1186/s13256-024-04363-z |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.